Sorrento Therapeutics, Inc. - Common Stock (SRNE)
$0.0005
0.0001 (16.67%)
SRNE Stock Quote Delayed 30 Minutes
SRNE Stock: California Testing Approval Stokes Sorrento Therapeutics
Sorrento Therapeutics is poised to roll out clinical testing trials in California. SRNE stock is up in pre-market trading on Wednesday as the country continues to post record Covid-19 diagnoses and hospitalizations.
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Unlock Louis Navellier's
? Stock Report – FREE:
Is ? a BUY?
Powered by Portfolio Grader
A
B
C
D
F
?
Unlock Louis Navellier's
? Stock Report to Find Out – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Investing legend Louis Navellier rates ? a "?." Unlock his ? Stock Analysis to find out why – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Fundamental Grade
Quantitative Grade
- Sales Growth ?
- Operating Margin Growth ?
- Earnings Growth ?
- Earnings Momentum ?
- Earnings Surprises ?
- Analyst Earnings Revisions ?
- Cash Flow ?
- Return on Equity ?
Previous Close
-
Market Cap
-
PE Ratio
-
EPS
-
Volume (Avg. Vol.)
32,479
Day's Range
$0.0005 - $0.0006
52-Week Range
$0.0001 - $0.09
Dividend & Yield
N/A (N/A)
SRNE Stock Predictions, Articles, and Sorrento Therapeutics, Inc. - Common Stock News
The Shock and Awe of Sorrento Therapeutics Is Long Gone
Sorrento Therapeutics was an early pandemic winner. But as the world closes in on multiple vaccines, SRNE stock looks to be too late.
Hopefuls Back Sorrento Therapeutics But Time Is a Factor
Investors seeking a longshot coronavirus play continue to eye SRNE stock despite Sorrento Therapeutics' high risk and continued volatility.
Sorrento Stock Doesn’t Offer Any Upside as Vaccine Frontrunners Emerge
The Covid-19 race is close to ending. It seems unlikely that Sorrento stock can pull a rabbit out of a hat with the frontrunners emerging.
Windows of Opportunity Are Tightening for Sorrento Therapeutics
Thanks to Sorrento Therapeutics’ all-out pivot to address the Covid-19 pandemic, SRNE stock initially became one of the most popular investments. But as both the vaccine and treatment race tighten, the risks multiply.
Don’t Bail on Sorrento Therapeutics Stock Just Yet
SRNE stock has tumbled as larger players have shown progress toward a vaccine. But this isn't just a vaccine play, and the story is far from over.
Avoid Sorrento Therapeutics, Which Is Still Burning Cash With No End In Sight
Avoid Sorrento Therapeutics which is still burning cash with no end in sight. SRNE stock will become more diluted as the company consistently raises cash.
Sorrento Therapeutics Hoping Better Late Than Never Works in Vaccine Competition
In this competition, Sorrento is a different beast because it's not just working on a vaccine, it's working on Covid-19 testing, neutralizing antibodies and preventive “shields,” among other products. That's a relevant, robust pipeline, but it hasn't been enough to prevent SRNE stock from sliding 61% from its 52-week high.
The Breakthrough for Sorrento Could Be Just Around the Corner
If you'd like to wager on a company with a packed clinical pipeline featuring potential Covid-19 treatments, SRNE stock is a great choice.
A Vulnerable Pipeline Continues to Weigh Down Sorrento Stock
Sorrento stock continues to be weighed down by the company's inefficacious product pipeline making it an incredibly risky investment.
Unless Sorrento Makes Solid Progress Soon, It Will Likely Go Below $5
SRNE stock is a speculative play in the race to develop a Covid-19 therapy
Is It Time to Buy Sorrento Stock After Its Month-Long Swoon?
Sorrento stock has lost 50% over the past month. Investors have grown impatient with the company's Covid-19 efforts. Time to buy or sell?
I Would Not Be Surprised If SRNE Stock Trades Below $5
SRNE stock is a purely speculative bet. The company has a deep pipeline of Covid-19 programs. But there is little progress or positive outcome.
Sorrento Stock Is Too Sick to Resuscitate
Sorrento Therapeutics stock has been punished in recent weeks. In this article we look at why Sorrento stock has fallen 50% since mid-October, and if the company's fortunes can be revived.
Sorrento Stock Is Still in this Fight but Better Buckle Up
Biotech companies typically live and die by headlines. SRNE stock has had better days, so they need one soon for the sake of its investors.
Sorrento Keeps Falling as the Pipeline Fails to Deliver
SRNE stock had its chance in 2020. But with its Covid-19 efforts failing to deliver concrete results, traders are dumping their shares.
Your First Instinct About Sorrento Therapeutics Is Probably Right
SRNE stock is down nearly 66% since August. The company is taking many swings at finding solutions for Covid-19, but it's runway simply isn't long enough.
Sorrento Therapeutics Is Charming But Read the Label
Undoubtedly, Sorrento Therapeutics’ Henry Ji has done a fantastic job marketing SRNE stock. But as the Covid-19 race narrows, the probability of winning declines significantly.
Sorrento Vaccine Hopes Are a Big ‘If’ With a Long Wait
SRNE stock won't appeal to many investors at this time. Click for news on its big hope among many plays.
Despite Pandemic Catalysts, Tread Carefully With Sorrento Stock
So, what's the play here? If its pandemic catalysts deliver, shares could soar back to double-digits. If not? The stock could tumble down to pre-pandemic price levels (under $3 per share). Bottom line: watch out, if you are looking to pounce on the pullback in SRNE stock.
